Addressing Antimicrobial Resistance and Stewardship: The Priority Antimicrobial Value and Entry (PAVE) Award

Antimicrobial-resistant infections affect more than two million people annually in the US alone, accounting for an estimated 23 000 deaths and estimated economic costs of $55 billion. Recent projections suggest that an estimated 300 million people worldwide could die prematurely in the next 35 years...

Full description

Saved in:
Bibliographic Details
Published inJAMA : the journal of the American Medical Association Vol. 318; no. 12; pp. 1103 - 1104
Main Authors Daniel, Gregory W, Schneider, Monika, McClellan, Mark B
Format Journal Article
LanguageEnglish
Published United States American Medical Association 26.09.2017
Subjects
Accounting
Anti-Infective Agents - economics
Anti-Infective Agents - therapeutic use
Antibiotics
Antiinfectives and antibacterials
Antimicrobial agents
Antimicrobial resistance
Colistin
Drug Discovery - economics
Drug resistance
Drug Resistance, Microbial
Economic impact
Health care expenditures
Humans
Infections
Medical personnel
Payments
Physicians
Public health
Risk Sharing, Financial
United States
Value-Based Health Insurance
Online AccessGet full text

Cover

More Information
Summary:Antimicrobial-resistant infections affect more than two million people annually in the US alone, accounting for an estimated 23 000 deaths and estimated economic costs of $55 billion. Recent projections suggest that an estimated 300 million people worldwide could die prematurely in the next 35 years because of antimicrobial-resistant infections. Physicians are more frequently prescribing antibiotics of last resort (such as colistin and carbapenem), raising concerns that once-curable infections will have no viable treatments. Here, Daniel et al talk about ways to address antimicrobial overuse and its payment structure.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0098-7484
1538-3598
DOI:10.1001/jama.2017.10164